Cargando…
Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly – a randomised, double-blinded trial
BACKGROUND: Exercise testing in conjunction with measurement of cardiac biomarkers NT-proBNP and cTnI is a useful tool for monitoring the effect of treatment on cardiac patients. Administering Pimobendan in dogs with degenerative mitral valve disease (DMVD) and cardiomegaly results in delaying the o...
Autores principales: | Iwanuk, Nayeli, Nolte, Ingo, Wall, Leona, Sehn, Maximiliane, Raue, Jonathan, Pilgram, Anna, Rumstedt, Katja, Bach, Jan-Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617668/ https://www.ncbi.nlm.nih.gov/pubmed/31288807 http://dx.doi.org/10.1186/s12917-019-1980-z |
Ejemplares similares
-
Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly
por: Iwanuk, Nayeli, et al.
Publicado: (2019) -
Clinical use of submaximal treadmill exercise testing and assessments of cardiac biomarkers NT-proBNP and cTnI in dogs with presymptomatic mitral regurgitation
por: Wall, Leona, et al.
Publicado: (2018) -
The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
por: Klein, Stephanie, et al.
Publicado: (2021) -
Significance of NT-proBNP and High-Sensitivity Troponin in Friedreich Ataxia
por: Legrand, Lise, et al.
Publicado: (2020) -
Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)